It is quite possible that the single agent ZEN-3694 dose escalation portion is complete and they have now found the maximally tolerated dose for ZEN-3694. Based on previous trial timelines from other presentations, this likely triggered 1) the start of the ZEN-3694/enzalutamide combo trial dose escalation and 2) expansion of the single agent ZEN-3694 to a larger population of patients at the optimal dose. Based on the start of recruiting for the combo trial, we know that #1 is happening. We may not hear about #2 until the AGM/Corporate Update. As San Fran wrote, it sure would be nice to hear about how those prostate tumors responded during the dose escalation.
BearDownAZ
